본문 바로가기
KERD
논문KCI 등재

Efficacy of Salvage Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis

조진현|김원석|김석진|김진철|윤상은
대한암학회 (Korean Cancer Association)|2023.07|Cancer Research and Treatment|제55권 제3호|pp. 1031-1047|DOI 10.4143/crt.2022.1658

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

Meta-analysisRegimenRelapsed/refractory large B-cell lymphomaPFS outcome
주제분류의학일반

초록

Purpose We intend to evaluate the efficacy of salvage treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) through meta-analysis.Materials and Methods R/R DLBCL trials were divided into two groups based on eligibility for autologous stem-cell transplantation (ASCT), and meta-analysis of each group was performed. Random effects models were used to estimate the 1-year progression-free survival (PFS) rate, and chimeric antigen receptor (CAR) T-cell therapy was used as reference treatment.Results Twenty-six ASCT-eligible cohorts from 17 studies comprising 2,924 patients and 59 ASCT-ineligible cohorts from 53 studies comprising 3,617 patients were included in the pooled analysis. In the ASCT-eligible group, the pooled 1-year PFS rate was 0.40 (95% confidence interval [CI], 0.15 to 0.65) for the CAR T-cell group and 0.34 (95% CI, 0.30 to 0.37) for the group with chemotherapy followed by ASCT intention. The two treatments were not significantly different in meta-regression analysis. In the ASCT-ineligible group, the pooled 1-year PFS was 0.40 (95% CI, 0.35 to 0.46) for CAR T-cell, and the highest primary outcome was 0.47 (95% CI, 0.37 to 0.57) for the tafasitamab group. CAR T-cell therapy showed significantly better outcomes than chemotherapy and therapies based on ibrutinib, lenalidomide, and selinexor. However, loncastuximab, polatuzumab plus bendamustine and rituximab, and the tafasitamab group showed no different efficacy than CAR T-cell therapy after adjusting for median number of previous lines of treatment.Conclusion Although several regimens were crudely grouped for classification, CAR T-cell therapy did not outperform chemotherapy followed by ASCT in the second-line setting or several recently developed agents in the ASCT-ineligible setting.

Abstract

Purpose We intend to evaluate the efficacy of salvage treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) through meta-analysis.Materials and Methods R/R DLBCL trials were divided into two groups based on eligibility for autologous stem-cell transplantation (ASCT), and meta-analysis of each group was performed. Random effects models were used to estimate the 1-year progression-free survival (PFS) rate, and chimeric antigen receptor (CAR) T-cell therapy was used as reference treatment.Results Twenty-six ASCT-eligible cohorts from 17 studies comprising 2,924 patients and 59 ASCT-ineligible cohorts from 53 studies comprising 3,617 patients were included in the pooled analysis. In the ASCT-eligible group, the pooled 1-year PFS rate was 0.40 (95% confidence interval [CI], 0.15 to 0.65) for the CAR T-cell group and 0.34 (95% CI, 0.30 to 0.37) for the group with chemotherapy followed by ASCT intention. The two treatments were not significantly different in meta-regression analysis. In the ASCT-ineligible group, the pooled 1-year PFS was 0.40 (95% CI, 0.35 to 0.46) for CAR T-cell, and the highest primary outcome was 0.47 (95% CI, 0.37 to 0.57) for the tafasitamab group. CAR T-cell therapy showed significantly better outcomes than chemotherapy and therapies based on ibrutinib, lenalidomide, and selinexor. However, loncastuximab, polatuzumab plus bendamustine and rituximab, and the tafasitamab group showed no different efficacy than CAR T-cell therapy after adjusting for median number of previous lines of treatment.Conclusion Although several regimens were crudely grouped for classification, CAR T-cell therapy did not outperform chemotherapy followed by ASCT in the second-line setting or several recently developed agents in the ASCT-ineligible setting.

참고문헌 (82)

  1. Teras LR, "2016 US lymphoid malignancy statistics by World Health Organization subtypes", CA Cancer J Clin, 66, pp.443~459 (2016)
  2. Sehn LH, "Diffuse large B-cell lymphoma", N Engl J Med, 384, pp.842~858 (2021)
  3. Coiffier B, "Long-term outcome of patients in the LNH-98. 5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients : a study by the Groupe d’Etudes des Lymphomes de l’Adulte", Blood, 116, pp.2040~2045 (2010)
  4. Gisselbrecht C, "Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era", J Clin Oncol, 28, pp.4184~4190 (2010)
  5. Schuster SJ, "Chimeric antigen receptor T cells in refractory B-cell lymphomas", N Engl J Med, 377, pp.2545~2554 (2017)
  6. Locke FL, "Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma", N Engl J Med, 386, pp.640~654 (2022)
  7. Kamdar M, "Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma(TRANSFORM) : results from an interim analysis of an open-label, randomised, phase 3 trial", Lancet, 399, pp.2294~2308 (2022)
  8. Neelapu SS, "Axicabtagene ciloleucel CAR T-cell the-rapy in refractory large B-cell lymphoma", N Engl J Med, 377, pp.2531~2544 (2017)
  9. Schuster SJ, "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma", N Engl J Med, 380, pp.45~56 (2019)
  10. Abramson JS, "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas(TRANSCEND NHL 001) : a multicentre seamless design study", Lancet, 396, pp.839~852 (2020)
  11. Bishop MR, "Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma", N Engl J Med, 386, pp.629~639 (2022)
  12. Roschewski M, "CAR T-cell therapy for large B-cell lymphoma : who, when, and how?", N Engl J Med, 386, pp.692~696 (2022)
  13. "NCCN clinical practice guidelines: B-cell lymphomas V5.2022" (2022)[URL]
  14. Sehn LH, "Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma", J Clin Oncol, 38, pp.155~165 (2020)
  15. Kalakonda N, "Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma(SADAL) : a single-arm, multinational, multicentre, open-label, phase 2 trial", Lancet Haematol, 7, pp.e511~22 (2020)
  16. Salles G, "Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma(L-MIND) : a multicentre, prospective, single-arm, phase 2 study", Lancet Oncol, 21, pp.978~988 (2020)
  17. Caimi PF, "Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma(LOTIS-2) : a multicentre, open-label, single-arm, phase 2 trial", Lancet Oncol, 22, pp.790~800 (2021)
  18. Stroup DF, "Meta-analysis of observational studies in epidemiology : a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology(MOOSE)group", JAMA, 283, pp.2008~2012 (2000)
  19. Kang HJ, "Irinotecan plus cisplatin and dexamethasone(ICD)combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with rituximab plus CHOP", Cancer Chemother Pharmacol, 62, pp.299~304 (2008)
  20. Fayad L, "Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone : a randomized, double-blind, placebo-controlled phase 2b trial", Leuk Lymphoma, 56, pp.2569~2578 (2015)
  21. Crump M, "Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas : NCIC-CTG LY. 12", J Clin Oncol, 32, pp.3490~3496 (2014)
  22. van Imhoff GW, "Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma : the ORCHARRD study", J Clin Oncol, 35, pp.544~551 (2017)
  23. Gyan E, "High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mito-xantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse : results of the R-NIMP GOELAMS study", Br J Haematol, 162, pp.240~249 (2013)
  24. Matasar MJ, "Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma", Blood, 122, pp.499~506 (2013)
  25. Kuhnl A, "R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma : results of the UK NRCI phase II randomised LEGEND trial", Ann Hematol, 99, pp.105~112 (2020)
  26. Witzig TE, "Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone(ROAD)in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma : results of a study of the Mayo Clinic Cancer Center Research Consortium(MCCRC)MC-0485 now known as academic and community cancer research united(ACCRU)", Am J Hematol, 92, pp.1004~1010 (2017)
  27. Pan J, "Phase I", II study of bendamustine in combination with ofatumumab, carboplatin, etoposide(BOCE)for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, 2021, pp.62, 590~597
  28. Witzens-Harig M, "The mTOR inhibitor temsirolimus added to rituximab combined with dexamethasone, cytarabine, and cisplatinum(R-DHAP)for the treatment of patients with relapsed or refractory DLBCL : results from the phase-II STORM trial", Hemasphere, 5, pp.e636~ (2021)
  29. Wang M, "Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma : a phase II clinical trial", Leukemia, 27, pp.1902~1909 (2013)
  30. Wagner-Johnston ND, "A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed", refractory diffuse large B-cell lymphoma, 2015, pp.56, 2863~2869
  31. Coyle L, "Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed", refractory aggressive B-cell non-Hodgkin lymphoma, 2020, pp.61, 2103~2112
  32. Sang W, "Phase II trial of co-administration of CD19-and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma", Cancer Med, 9, pp.5827~5838 (2020)
  33. Lopez A, "GEMOX-R regimen is a highly effective salvage regimen in patients with refractory", relapsing diffuse large-cell lymphoma : a phase II study, 2008, pp.80, 127~132
  34. Czuczman MS, "A phase 2", 3 multicenter, randomized, open-lbel study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma, 2017, pp.23, 4127~4137
  35. Ohmachi K, "Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma", J Clin Oncol, 31, pp.2103~2109 (2013)
  36. Vacirca JL, "Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma", Ann Hematol, 93, pp.403~409 (2014)
  37. Dang NH, "Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed", refractory aggressive B-cell non-Hodgkin lymphoma, 2018, pp.182, 583~586
  38. Murayama K, "Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma", Ann Hematol, 101, pp.979~989 (2022)
  39. Pettengell R, "Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma : post-hoc analyses from a phase III trial", Br J Haematol, 174, pp.692~699 (2016)
  40. Joshi M, "Outpatient rituximab, ifosfamide, etoposide(R-IE)in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantation", Leuk Lymphoma, 61, pp.91~97 (2020)
  41. Pettengell R, "Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation : a phase 3, randomized, multicentre trial(PIX306)", Br J Haematol, 188, pp.240~248 (2020)
  42. Lugtenburg PJ, "Rituximab-PECC induction followed by(90)Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT : results from a phase II HOVON study", Br J Haematol, 187, pp.347~355 (2019)
  43. Hu J, "Combination of decitabine and a modified regimen of cisplatin, cytarabine and dexamethasone : a potential salvage regimen for relapsed or refractory diffuse large B-cell lymphoma after second-line treatment failure", Front Oncol, 11, pp.687374~ (2021)
  44. Wilson WH, "Phase 1b", 2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed, Leuk Lymphoma, pp.2021, 62[DOI]
  45. Hess G, "A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma : final results of the prospective, multicentre GOAL trial", Br J Haematol, 198, pp.482~491 (2022)
  46. Palazon-Carrion N, "Lenalidomide plus R-GDP(R2-GDP)in relapsed", refractory diffuse large B-cell lymphoma : final results of the R2-GDP-GOTEL trial and immune biomarker subanalysis, 2022, pp.28, 3658~3668
  47. Herrera AF, "Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma", Am J Hematol, 95, pp.18~27 (2020)
  48. Younes A, "Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia : a phase 1", 2a study, 2019, pp.6, e67~78
  49. Graf SA, "Ibrutinib monotherapy in relapsed or refractory, transformed diffuse large B-cell lymphoma", Clin Lymphoma Myeloma Leuk, 21, pp.176~181 (2021)
  50. Zinzani PL, "Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma : a phase 2 trial", Clin Lymphoma Myeloma Leuk, 11, pp.462~466 (2011)
  51. Houot R, "Obinutuzumab plus Lenalidomide(GALEN)for the treatment of relapse", refractory aggressive lymphoma : a phase II LYSA study, 2019, pp.33, 776~780
  52. Major A, "Phase I", II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas, 2022, pp.107, 1608~1618
  53. Terui Y, "A phase 2 study of polatuzumab vedotin+bendamustine +rituximab in relapsed", refractory diffuse large B-cell lymphoma, 2021, pp.112, 2845~2854
  54. Sehn LH, "Polatuzumab vedotin plus bendamustine and rituximab in relapsed", refractory DLBCL : survival update and new extension cohort data, 2022, pp.6, 533~543
  55. Morschhauser F, "Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma : final results from a phase 2 randomised study(ROMULUS)", Lancet Haematol, 6, pp.e254~65 (2019)
  56. Jurczak W, "Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma", Ann Oncol, 29, pp.1266~1272 (2018)
  57. Morschhauser F, "Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation", Blood, 110, pp.54~58 (2007)
  58. Arnason JE, "Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant", Acta Haematol, 133, pp.347~353 (2015)
  59. Smith SM, "Temsirolimus has activity in non-mantle cell non-Hodgkin’s lymphoma subtypes : the University of Chicago phase II consortium", J Clin Oncol, 28, pp.4740~4746 (2010)
  60. Coiffier B, "A multicentre, phase II trial of ofatumumab monotherapy in relapsed", progressive diffuse large B-cell lymphoma, 2013, pp.163, 334~342
  61. Barnes JA, "Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma", Haematologica, 98, pp.615~619 (2013)
  62. de Vos S, "A phase II study of dacetuzumab(SGN-40)in patients with relapsed diffuse large B-cell lymphoma(DLBCL)and correlative analyses of patient-specific factors", J Hematol Oncol, 7, pp.44~ (2014)
  63. Papadopoulos KP, "A multicenter phase II study of sepantronium bromide(YM155)plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma", Leuk Lymphoma, 57, pp.1848~1855 (2016)
  64. Puvvada SD, "A phase II study of belinostat(PXD101)in relapsed and refractory aggressive B-cell lymphomas : SWOG S0520", Leuk Lymphoma, 57, pp.2359~2369 (2016)
  65. Coiffier B, "A phase II, single-arm, multicentre study of coltuximab ravtansine(SAR3419)and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma", Br J Haematol, 173, pp.722~730 (2016)
  66. Assouline SE, "Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma", Blood, 128, pp.185~194 (2016)
  67. Batlevi CL, "A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma", Br J Haematol, 178, pp.434~441 (2017)
  68. Younes A, "Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma", Haematologica, 102, pp.2104~2112 (2017)
  69. Ribrag V, "Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia : results of a phase II study", Haematologica, 102, pp.903~909 (2017)
  70. Trneny M, "A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine(SAR3419)in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy", Haematologica, 103, pp.1351~1358 (2018)
  71. Burke JM, "An open-label, phase II trial of entospletinib(GS-9973), a selective spleen tyrosine kinase inhibitor, in diffuse large B-cell lymphoma", Clin Lymphoma Myeloma Leuk, 18, pp.e327~31 (2018)
  72. Barnes JA, "Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma : results of a phase II study", Hematol Oncol, 36, pp.633~637 (2018)
  73. Zaja F, "Single-agent panobinostat for relapsed", refractory diffuse large B-cell lymphoma : clinical outcome and correlation with genomic data : a phase 2 study of the Fondazione Italiana Linfomi, 2018, pp.59, 2904~2910
  74. Galanina N, "University of Chicago phase II consortium trial of selumetinib(MEKi)demonstrates low tolerability and efficacy in relapsed DLBCL", Br J Haematol, 181, pp.264~267 (2018)
  75. Ansell SM, "Nivolumab for relapsed", refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation : a single-arm, phase II study, 2019, pp.37, 481~489
  76. Lenz G, "Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma", Leukemia, 34, pp.2184~2197 (2020)
  77. Mussetti A, "Second-line CAR T cells for lymphomas", Lancet, 399, pp.2247~2249 (2022)
  78. Shargian L, "Chimeric antigen receptor T-cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma : A systematic review and meta-analysis", Br J Haematol, 198, pp.838~846 (2022)
  79. Shadman M, "Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission", Blood, 139, pp.1330~1339 (2022)
  80. Neelapu SS, "Comparison of 2-year outcomes with CAR T cells(ZUMA-1)vs salvage chemotherapy in refractory large B-cell lymphoma", Blood Adv, 5, pp.4149~4155 (2021)
  81. Maziarz RT, "Indirect comparison of tisagenlecleucel and historical treatments for relapsed", refractory diffuse large B-cell lymphoma, 2022, pp.6, 2536~2547
  82. Nowakowski GS, "Tafasitamab plus lenalidomide versus pola-BR, R2, and CAR T : comparing outcomes from RE-MIND2, an observational, retrospective cohort study in relapsed", refractory diffuse large B-cell lymphoma, 2021, pp.138(Supp 1), 183~

관련 논문AI추천

Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts박용, 강혜진, 고영일, 곽재용, 권지현, 김민경, 김석진, 김원석, 김진석, 김효정, 도영록, 박병배, 서철원, 손병석, 신호진, 양덕환, 엄현석, 오성용, 원종호, 유쾌한, 윤덕현, 윤환정, 이경원, 이성윤, 이원식, 이준호, 이호섭, 정성현, 조재철, 최윤석, 홍대식대한암학회 · Cancer Research and Treatment2023 · 제55권 제1호Advances in T-Cell–Directed Immunotherapy for Adult Mature B-Cell Lymphoma: A Comprehensive Review of CAR T-Cell and Bispecific Antibody Therapies김석진, 김진철대한암학회 · Cancer Research and Treatment2025 · 제57권 제4호Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients이석, 김유진, 김종욱, 김희제, 민우성, 민창기, 박장원, 엄기성, 윤재호, 이성은, 이종욱, 전영우, 조석구대한내과학회 · The Korean Journal of Internal Medicine2015 · 제30권 제3호Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies김석진, 김원석, Yoon Sang Eun대한진단검사의학회 · Annals of Laboratory Medicine2024 · 제44권 제3호Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement고옥배, 서철원, 허주령, Geundoo Jang, Shin Kim대한내과학회 · The Korean Journal of Internal Medicine2008 · 제23권 제4호Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP강혜련, 김동완, 김미소, 김범석, 김철우, 김태민, 송우정, 전윤경, 정재우, 조경민, 하혜림, 허대석대한내과학회 · The Korean Journal of Internal Medicine2019 · 제34권 제4호

이 간행물의 다른 논문 (32건)

Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy조원경, 안용찬, 엄준원, 이종훈, 정재욱, 임채홍, 조현민, 유규상, 지의규pp. 707-719Cellular Dormancy in Cancer - Mechanisms and Potential Targeting Strategies이호영, 민혜영pp. 720-736Identification of Genes Involved in EGF-Induced Apoptosis Using CRISPR/Cas9 Knockout Screening: Implications for Novel Therapeutic Targets in EGFR-Overexpressing Cancers이주호, 전승혁, 김용섭, 전상록, 김재식, 우홍균pp. 737-745Immunogenicity and Safety of Vaccines Against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study이충근, 박소라, 김규현, 안진영, 이연정, 염준섭, 정민규, 라선영, 김신영, 신상준, 김정호, 이경화, 정수진, 최준용, 구남수, 범승훈, 백예지pp. 746-757Recent Trends of Medical Expenses Associated with Radiation Therapy in Korea Based on HIRA Big Data허승재, 박원, 안용찬, 양경미, 이정은pp. 758-765
원문 보기